Online inquiry

IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4895MR)

This product GTTS-WQ4895MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ACVR2 gene. The antibody can be applied in Cachexia, Type 2 diabetes, Sarcopenia research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001278579.2; NM_001106.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 92; 93
UniProt ID P27037; Q13705
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ4895MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13191MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-04950615
GTTS-WQ10560MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY­3074828
GTTS-WQ10120MR IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LAG-525
GTTS-WQ4229MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB029
GTTS-WQ11318MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-524
GTTS-WQ13102MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-03446962
GTTS-WQ10551MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA LY­3074828
GTTS-WQ10906MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MABp1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW